Originally published as JCO Early Release 10.1200/JCO.2005.06.146 on January 31 2005
Journal of Clinical Oncology, Vol 23, No 10 (April 1), 2005: pp. 2215-2223
© 2005 American Society of Clinical Oncology.
Meta-Analysis to Evaluate the Role of Interferon in Follicular Lymphoma
A.Z.S. Rohatiner,
W.M. Gregory,
B. Peterson,
E. Borden,
P. Solal-Celigny,
A. Hagenbeek,
R.I. Fisher,
M. Unterhalt,
R. Arranz,
T. Chisesi,
A. Aviles,
T.A. Lister
From St Bartholomew's Hospital, London, UK; University of Minnesota, Minneapolis, MN; Taussig Cancer Center, Cleveland, OH; Centre Jean Bernard, Le Mans, France; University Medical Center, Utrecht, The Netherlands; Wilmot Cancer Center, University of Rochester, Rochester, NY; Georg-August-University, Gottingen, Germany; Hospital Universitario de la Princesa, Madrid, Spain; Ospedale Civile, Venice, Italy; Oncology Hospital, IMSS, Mexico City, Mexico
Address reprint requests to A.Z.S. Rohatiner, MD, FRCP, Department of Medical Oncology, St Bartholomew's Hospital, 45 Little Britain, London, EC1A 7BE, United Kingdom; e-mail: ama.rohatiner{at}cancer.org.uk
PURPOSE: To determine whether interferon (IFN) - 2, when given with or following chemotherapy, influences response rate, remission duration, and survival in newly diagnosed patients with follicular lymphoma.
PATIENTS AND METHODS: Ten phase III studies evaluating the role of IFN-2 in 1,922 newly diagnosed patients with follicular lymphoma were analyzed. Updated individual patient data were used to perform meta-analyses for response, survival, and remission duration.
RESULTS: The addition of IFN-2 to initial chemotherapy did not significantly influence response rate. An overall meta-analysis for survival showed a significant difference in favor of IFN-2, but also showed significant heterogeneity between studies. Further analyses were carried out in order to explain this heterogeneity, and to define the circumstances in which IFN-2 prolonged survival. The survival advantage was seen when IFN-2 was given: (1) in conjunction with relatively intensive initial chemotherapy (2P = .00005), (2) at a dose  5 million units (2P = .000002), (3) at a cumulative dose 36 million units per month (2P = .000008), and (4) with chemotherapy rather than as maintenance therapy (P = .004). With regard to remission duration, there was also a significant difference in favor of IFN-2, irrespective of the intensity of chemotherapy used, IFN dose, or whether IFN was given as a maintenance strategy or with chemotherapy.
CONCLUSION: When given in the context of relatively intensive initial chemotherapy, and at a dose 5 million units ( 36 x 106 units per month), IFN-2 prolongs survival and remission duration in patients with follicular lymphoma.
Supported in part by a grant from Schering-Plough.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Morschhauser, M. Dreyling, A. Rohatiner, F. Hagemeister, and A. Bischof Delaloye
Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence
Oncologist,
October 1, 2009;
14(suppl_2):
17 - 29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hochster, E. Weller, R. D. Gascoyne, T. M. Habermann, L. I. Gordon, T. Ryan, L. Zhang, N. Colocci, S. Frankel, and S. J. Horning
Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study
J. Clin. Oncol.,
April 1, 2009;
27(10):
1607 - 1614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hagenbeek
Maintenance or Eradication of Residual Disease in Indolent Lymphoma: Where Do We Stand?
J. Clin. Oncol.,
April 1, 2009;
27(10):
1540 - 1542.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Maby-El Hajjami, P. Ame-Thomas, C. Pangault, O. Tribut, J. DeVos, R. Jean, N. Bescher, C. Monvoisin, J. Dulong, T. Lamy, et al.
Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase
Cancer Res.,
April 1, 2009;
69(7):
3228 - 3237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Salles, N. Mounier, S. de Guibert, F. Morschhauser, C. Doyen, J.-F. Rossi, C. Haioun, P. Brice, B. Mahe, R. Bouabdallah, et al.
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
Blood,
December 15, 2008;
112(13):
4824 - 4831.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Marcus, K. Imrie, P. Solal-Celigny, J. V. Catalano, A. Dmoszynska, J. C. Raposo, F. C. Offner, J. Gomez-Codina, A. Belch, D. Cunningham, et al.
Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma
J. Clin. Oncol.,
October 1, 2008;
26(28):
4579 - 4586.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bendandi
Aiming at a Curative Strategy for Follicular Lymphoma
CA Cancer J Clin,
September 1, 2008;
58(5):
305 - 317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sebban, P. Brice, R. Delarue, C. Haioun, B. Souleau, N. Mounier, N. Brousse, P. Feugier, H. Tilly, P. Solal-Celigny, et al.
Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA Study
J. Clin. Oncol.,
July 20, 2008;
26(21):
3614 - 3620.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Vose
Maintenance Rituximab-Should It Be Given to Every Patient with Follicular Lymphoma?
ASCO Educational Book,
January 1, 2008;
2008(1):
386 - 390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Weingart, F. A. Rehan, H. Schulz, F. Naumann, I. Knauel, C. B. J. Bohlius, and A. Engert
Sixth Biannual Report of the Cochrane Haematological Malignancies Group Focus on Non-Hodgkin Lymphoma
J Natl Cancer Inst,
September 5, 2007;
99(17):
E1 - E1.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H.J. van Oers
Rituximab maintenance therapy: a step forward in follicular lymphoma
Haematologica,
June 1, 2007;
92(6):
826 - 833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Salles
Clinical Features, Prognosis and Treatment of Follicular Lymphoma
Hematology,
January 1, 2007;
2007(1):
216 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. J. van Oers, R. Klasa, R. E. Marcus, M. Wolf, E. Kimby, R. D. Gascoyne, A. Jack, M. van't Veer, A. Vranovsky, H. Holte, et al.
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Blood,
November 15, 2006;
108(10):
3295 - 3301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sebban, N. Mounier, N. Brousse, C. Belanger, P. Brice, C. Haioun, H. Tilly, P. Feugier, R. Bouabdallah, C. Doyen, et al.
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Blood,
October 15, 2006;
108(8):
2540 - 2544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Redfern, T. H. Guthrie, A. Bessudo, J. J. Densmore, P. R. Holman, N. Janakiraman, J. P. Leonard, R. L. Levy, R. G. Just, M. R. Smith, et al.
Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin's Lymphoma Resulting in Durable Clinical Responses
J. Clin. Oncol.,
July 1, 2006;
24(19):
3107 - 3112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. Fisher, M. LeBlanc, O. W. Press, D. G. Maloney, J. M. Unger, and T. P. Miller
New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma
J. Clin. Oncol.,
November 20, 2005;
23(33):
8447 - 8452.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Lister
Improved Survival for Patients With Follicular Lymphoma
J. Clin. Oncol.,
August 1, 2005;
23(22):
4830 - 4831.
[Full Text]
[PDF]
|
|
|
|
